DSL(SH:603233) Quan Jing Wang·2025-06-25 12:03Core Viewpoint - Dazhonglin has implemented a high dividend payout strategy, distributing a total of 7.02 billion yuan in cash dividends for the year, reflecting a strong commitment to shareholder returns and confidence in its operational strength amid market complexities [1][2]. Financial Performance - In 2024, Dazhonglin achieved a revenue of 26.497 billion yuan and a net profit attributable to shareholders of 915 million yuan [1]. - For the first quarter of 2025, the company reported a revenue of 6.956 billion yuan, representing a year-on-year growth of 3.02%, and a net profit of 460 million yuan, showing a year-on-year increase of 15.45% [1][2]. Dividend Policy - The company distributed a cash dividend of 3.1 yuan per 10 shares (including tax) to all shareholders, totaling 351 million yuan [1]. - Dazhonglin has maintained a high dividend payout ratio of 76.73%, with a dividend yield of 3.98%, ranking among the top in its sector [1][2]. - Since its listing in 2017, Dazhonglin has cumulatively distributed cash dividends amounting to 3.355 billion yuan, with a dividend payment ratio of 76.73% and a financing payout ratio of 98.84% [1]. Store Expansion and Market Position - As of March 2025, Dazhonglin operated a total of 16,622 stores, including 6,239 franchise stores and 10,383 direct stores, marking a net increase of 2,588 stores since the beginning of 2024 [2]. - The company aims to enhance its market share in already covered regions, leveraging its scale advantages to further solidify its position as a leading chain pharmacy in China [2]. Future Outlook - Dazhonglin is expected to strengthen its leadership in the pharmaceutical retail sector, driven by ongoing industry transformations and increasing consumer demand for quality and personalized health products [2].